Analytical results from the RAINBOW study provided a regimen of ramucirumab and paclitaxel for patients with gastric/gastroesophageal adenocarcinoma. This is considered a new advancement in the treatment of advanced gastric/gastro-oesophageal cancer.

Pembrolizumab (Keytruda) is one of a number of immunosuppressive cancer drugs. The following article briefly presents the results of a newly published study of Pembrolizumab (Keytruda) for advanced gastric and esophageal cancer.